Wells Fargo & Company Vincerx Pharma, Inc. Transaction History

Wells Fargo & Company

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.07 - $8.06 $28 - $217	27 Added 20.3%	160 $0
Q4 2023 Feb 09, 2024	BUY	$0.62 - $1.18 $4 - $8	7 Added 5.56%	133 $0
Q3 2023 Nov 13, 2023	BUY	$0.66 - $1.38 $1 - $2	2 Added 1.61%	126 $0
Q2 2023 Aug 15, 2023	BUY	$0.88 - $1.9 $4 - $9	5 Added 4.2%	124 $0
Q1 2023 May 12, 2023	BUY	$0.9 - $1.51 $1 - $3	2 Added 1.71%	119 $0
Q4 2022 Feb 13, 2023	BUY	$0.64 - $1.32 $2 - $5	4 Added 3.54%	117 $0
Q3 2022 Nov 14, 2022	BUY	$0.0 - $1.72 $0 - $10	6 Added 5.61%	113 $0
Q2 2022 Aug 12, 2022	SELL	$0.0 - $0.0 $0 - $0	-11,881 Reduced 99.11%	107 $0
Q1 2022 May 16, 2022	SELL	$0.0 - $0.0 $0 - $0	-5,351 Reduced 30.86%	11,988 $48,000
Q4 2021 Feb 14, 2022	SELL	$0.0 - $0.0 $0 - $0	-18,302 Reduced 51.35%	17,339 $176,000
Q3 2021 Nov 15, 2021	BUY	$0.0 - $0.0 $0 - $0	29,141 Added 448.32%	35,641 $576,000
Q2 2021 Aug 16, 2021	BUY	$0.0 - $27.0 $0 - $74,034	2,742 Added 72.96%	6,500 $84,000
Q1 2021 May 13, 2021	BUY	$22.6 - $31.0 $51,030 - $69,998	2,258 Added 150.53%	3,758 $72,000
Q4 2020 Feb 09, 2021	BUY	$12.85 - $19.95 $19,275 - $29,925	1,500 New	1,500 $31,000

4.8M

Ticker VINC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,189,800
Market Cap $26.3M
Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.